Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in ...

Upstream Bio has dosed the first subject in the randomised Phase II trial of verekitug, an antibody antagonist targeting the thymic stromal lymphopoietin (TSLP) receptor, in individuals with chronic ...

Phase 2 trial launched for verekitug in COPD, expanding treatment indications for severe respiratory conditions. Top data expected in 2026.

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) ...

COPD represents the third indication in verekitug’s development program, which also includes ongoing Phase 2 trials in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma.

Verekitug is currently being evaluated in three separate global, placebo-controlled, randomized Phase 2 clinical trials: the VIBRANT trial (NCT06164704) in patients with chronic rhinosinusitis ...

WALTHAM, Mass. - Upstream Bio, Inc. (NASDAQ:UPB) has dosed the first patient in its Phase 2 clinical trial evaluating verekitug for chronic obstructive pulmonary disease (COPD), the company announced ...

Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – ...

WALTHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...

WALTHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...